Lipoxen to develop a super-generic ribavirin
This article was originally published in Scrip
Executive Summary
A super-generic nanoparticle formulation of ribavirin which is targeted to the liver will be the first product worked on by a new collaboration between the AIM-listed firm Lipoxen and researchers at the University of Nottingham in the UK.